LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM (MIRENA) FOR ABNORMAL UTERINE BLEEDING- A USEFUL TOOL IN THE COVID TIMES
Article Sidebar
Main Article Content
Abstract
Objectives:
To assess the effectiveness of the Levonorgestrel-releasing intrauterine system (LNG-IUS) in improving heavy menstrual bleeding (HMB) and evaluate satisfaction rates among women with heavy menstrual bleeding, treated with LNG–IUS.
Material and methods: This prospective observational study with a one-year follow-up included 73 women of reproductive age 20 – 50 years with complaints of heavy menstrual bleeding (HMB). They presented to the Gynae ward and the outpatient department (OPD) of Khyber Teaching Hospital, Peshawar, Pakistan. Patients with more than 3 cm fibroids, pelvic inflammatory disease, bleeding of unknown cause, and any known pelvic malignancy were excluded. LNG-IUS (Mirena) was inserted in OPD routinely and in Operation Theater under anesthesia where the cervix could not be dilated. Patients were followed up in OPD at one month, 3 months, six months, and one year. Improvement in symptoms, satisfaction level, and Hemoglobin (Hb) before and after the procedure was documented on a Proforma.
RESULTS: There was a progressive resolution in the amount of bleeding in patients followed at 1-month, 3-month, six months, and one year. The satisfaction rate was 92%. There was an improvement in Hb in 97% of patients. Only 04 out of 73 patients needed a hysterectomy.
CONCLUSION: Levonorgestrel-releasing intrauterine system (LNG-IUS) is an effective and tolerated treatment option for abnormal uterine bleeding. In the Covid times, it proved to be an effective first-line management of AUB. We recommend its use after careful selection of patients and also recommend a good counseling session before its use.
Keywords: Abnormal uterine bleeding, heavy menstrual bleeding, LNG – IUS.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.
